Key Highlights

  • Third-quarter Revenue fell 17% to USD 21.6 million from USD 26.1 million, which management tied to reduced spending at a few large customers and pharmaceutical budget delays.
  • Adjusted EBITDA rose to USD 6.3 million from USD 5.1 million, lifting the Margin to about 29% from about 20% a year earlier, an improvement of more than 900 basis points.
  • GAAP Net Income was USD 1.2 million, or USD 0.06 per share, versus USD 0.8 million, or USD 0.04, while non-GAAP net income was USD 3.8 million, or USD 0.20 per diluted share.
  • Management updated 2026 revenue guidance to USD 87 million to USD 93 million and maintained adjusted EBITDA guidance of USD 21 million to USD 25 million.

Revenue Slips 17% While Margins Widen

OptimizeRx (NASDAQ:OPRX) held its third-quarter call on November 12, 2026, saying it issued its Earnings release that afternoon. The company sells point-of-care Marketing and data tools that reach doctors and patients through electronic health record systems. Revenue declined 17%, which the finance chief attributed to a limited number of large customers, including some who used a lower-margin managed services offering, and to market delays linked to pricing uncertainty. Expenses fell USD 5.1 million to USD 18.9 million despite USD 0.7 million of severance, and management expects full-year gross margin in the low 70% range. Operating Cash Flow was USD 12.9 million for the first three quarters of 2026.

A Guidance Update That Leans on the Fourth Quarter

Management said contracted revenue for 2026 continues to track about 20% below the prior year, leaving more revenue to secure and recognize in the fourth quarter. The company set revenue guidance at USD 87 million to USD 93 million, and the material does not give the earlier range. Management acknowledged higher execution risk but pointed to a previously displaced top five client that began spending again in the fourth quarter, plus pent-up Demand and the 2027 request-for-proposal season. Net revenue retention fell to 83%, which management said reflected a few large accounts optimizing spend rather than broad churn. Average revenue per top 20 pharmaceutical manufacturer was USD 2.5 million, and revenue per employee was USD 706,000.

Programmatic Partnerships, Debt Paydown and a CFO Handover

The company has connected its network of more than 450 health record systems and over 1.1 million verified professionals to three programmatic platforms: DeepIntent, The Trade Desk and PulsePoint. Management said these three account for roughly 60% to 70% of Volume in that space, though revenue from the partners is still at an early stage. Cash was USD 22.3 million versus USD 23.4 million at year-end, and debt fell to USD 13.4 million after USD 6.3 million of principal payments, then to USD 10.4 million after a further USD 3 million paid after quarter end. Andy D'Silva becomes CFO on January 1, 2027.

Where Things Stand

Not yet, since margins are rising while sales are shrinking. OptimizeRx (NASDAQ:OPRX) delivered an adjusted EBITDA margin of about 29% on revenue down 17%, and it maintained its profit guidance while updating revenue guidance. Offsetting that, contracted revenue is about 20% lower and the year depends on fourth-quarter conversion. Management said it sees the revised outlook as timing of customer spending rather than a lasting change in demand. Next markers are fourth-quarter results, the programmatic ramp with PulsePoint in November and the CFO transition at the start of 2027.